Status:
COMPLETED
PREVALENCE OF Anti-CCP POSITIVITY AND SUBCLINICAL SIGNS OF INFLAMMATION IN PATIENTS WITH NEW ONSET OF NON-SPECIFIC MUSCULOSKELETAL SYMPTOMS
Lead Sponsor:
Fraunhofer Institute for Translational Medicine and Pharmacology ITMP
Collaborating Sponsors:
Bristol-Myers Squibb
Goethe University
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18-65 years
Brief Summary
Non-interventional, prospective, observational study to assess the relative risk of anti-CCP positive patients to develop (subclinical) signs of inflammation in accordance with early Rheumatoid Arthri...
Detailed Description
Studies of early arthritis cohorts have shown that a large number of early arthritis patients cannot be accurately diagnosed at their first visit, and hence are often referred as undifferentiated arth...
Eligibility Criteria
Inclusion
- New onset of non-specific MSK symptoms, including, but not limited to, arthralgia of the hands and the large joints such as wrists, knees, and shoulders
- Written informed consent obtained prior to the initiation of any study protocol-required procedures
- General understanding of study procedure and informed consent
- Age ≥ 18 and ≤ 65 years
Exclusion
- RA diagnosed according to modified EULAR/ACR (american college of rheumatology)-criteria
- Other known arthritis
- Other known reasons for MSK symptoms, e.g. mechanical, traumatic, etc.
- MSK symptoms previously reported at another (general) practice
- Alcohol, drug or chemical abuse
- Underage or incapable patients
Key Trial Info
Start Date :
April 27 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 15 2022
Estimated Enrollment :
986 Patients enrolled
Trial Details
Trial ID
NCT03267147
Start Date
April 27 2017
End Date
February 15 2022
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CIRI
Frankfurt am Main, Hessia, Germany, 60596